Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 0: clinchem.2007.085688v1, 2007; 10.1373/clinchem.2007.085688
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.085688v1
53/12/2193    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masiá, M.
Right arrow Articles by Gutiérrez, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masiá, M.
Right arrow Articles by Gutiérrez, F.

Received on January 12, 2007
Accepted on September 28, 2007

Infectious Disease

Midregional ProA-Type Natriuretic Peptide and Carboxy-Terminal Provasopressin May Predict Prognosis in Community-Acquired Pneumonia

Mar Masiá 1*, Jana Papassotiriou 2, Nils G. Morgenthaler 2, Ildefonso Hernández 3, Conrado Shum 4, Félix Gutiérrez 1

1 Infectious Diseases Unit, Internal Medicine Department, Hospital General Universitario de Elche, Alicante, Spain
2 Research Department, BRAHMS AG, Hennigsdorf/Berlin, Germany
3 Public Health Department, Universidad Miguel Hernández, Elche, Spain
4 Pneumology Section, Hospital General Universitario de Elche, Alicante, Spain

* To whom correspondence should be addressed. E-mail: marmasia{at}ya.com.

Background: Markers to better assess severity of disease in patients with community-acquired pneumonia (CAP) would help improve medical care of this condition. The hemodynamic biomarkers carboxy-terminal provasopressin (CT-proAVP; copeptin) and midregional proatrial natriuretic peptide (MR-proANP) are increased under septic conditions, in which MR-proANP has been described as a prognostic predictor. We aimed to explore the diagnostic accuracy of MR-proANP and CT-proAVP to predict mortality in patients with CAP.

Methods: We conducted a prospective observational study of patients with CAP. We measured biomarkers in serum samples obtained at diagnosis and performed univariate and multivariate analyses to identify potential predictors of mortality.

Results: CT-proAVP and MR-proANP concentrations were measured in 173 patients. We found a positive correlation between pneumonia severity index (PSI) and MR-proANP (rs = 0.68, P <0.0001) and between PSI and CT-proAVP (rs = 0.44, P <0.0001). Median (interquartile range) CT-proAVP and MR-proANP values were 8.2 (5.3–16.8) and 73.6 (44.6–144.0) pmol/L, respectively. Nonsurvivors had significantly higher MR-proANP and CT-proAVP than survivors (median 259.0 vs 71.8 pmol/L, P = 0.01, and 24.9 vs 8.1 pmol/L, P = 0.03, respectively). In multivariate analysis including PSI, procalcitonin, C-reactive protein, lipopolysaccharide-binding protein, CT-proAVP, and MR-proANP concentrations, only CT-proAVP remained an independent predictor of death (odds ratio 1.05, P = 0.007). Cutoff values of >18.9 pmol/L for CT-proAVP and >227 pmol/L for MR-proANP showed the highest diagnostic accuracy to predict mortality.

Conclusions: CT-proAVP and MR-proANP may be used to predict prognosis in patients with CAP.


The following articles in journals at HighWire Press have cited this article:


Home page
 ERRHome page
A. Lacoma, C. Prat, F. Andreo, and J. Dominguez
Biomarkers in the management of COPD
Eur. Respir. Rev., June 1, 2009; 18(112): 96 - 104.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.